comscoreBreast Cancer, a CEO, and a New Nonhormonal Birth Control

Breast Cancer, a CEO, and a New Nonhormonal Birth Control

Saundra Pelletier, CEO and founder of Evofem Biosciences, discusses working through breast cancer treatment and her company's new nonhormonal contraceptive gel for women.
Jun 25, 2021
00:00
Download
00:00

Saundra Pelletier was diagnosed with stage III breast cancer while her company was conducting phase III clinical trials on Phexxi, a nonhormonal contraceptive gel for women. She describes herself as a mother, daughter, CEO, and trailblazer. She has more than two decades of experience of executive leadership at companies and nonprofits focusing on women’s health.

Listen to the episode to hear Saundra discuss:

  • how she led her company without taking a leave of absence while being treated for breast cancer

  • how breast cancer changed her

  • how Phexxi, a nonhormonal birth control gel, was developed, how it works, and why it's safe for women who’ve been diagnosed with breast cancer

  • her advice for women who’ve just been diagnosed with breast cancer

See full product information at Phexxi.com. Do not use if you have a history of repeated urinary tract problems. Side effects include vaginal burning, itching, discharge, genital discomfort, yeast infection, urinary tract infection or bacterial vaginosis. Phexxi does not protect against STIs.



About the guest
 
Saundra Pelletier headshot
Sandra Pelletier

Saundra Pelletier is the CEO and founder of Evofem Biosciences.

— Last updated on July 31, 2022, 10:20 PM

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate